1. Kainan Health: annual mid-year net profit forecast 80.73%, up 47.83% in the first half of 2021; the company's wholly-owned subsidiary, Kiyon Beauty, is committed to innovation and development of cellular level skin repair technology, the core products used in the world's leading clinical-grade bio-protein gene recombination and autonomous Patented protein compounding technology, effective in the field of anti-aging repair and beauty. The main reason for the change in the company's performance is that the downstream market of the product has been opened, no longer affected by the epidemic, the industry's boom index is also gradually recovered. 2021, the company seized all the business opportunities of the recovery of the global consumer, and launched a variety of new products as well as improve the industrial chain so as to realize the performance of the sharp rise.
2. Aoyuan Meigu: annual mid-year net profit forecast 127.46%, up 178.03% in the first half of 2021; the company's wholly-owned subsidiary, Guangzhou Aomei and KD *** with the formation of a joint venture, and by the joint venture company in the domestic agent products. kD was founded in South Korea, from the main business can be seen in the sale of medical cosmetic devices, as well as cosmetic active raw materials, development and research of high-tech companies. Development and research of high-tech companies. The reason for the surge in performance and the factors brought about by the consolidation of the second quarter of the acquisition of zhejiang liantianmei company. The first half of last year due to the impact of the epidemic, which led to the production and sales of chemical fiber segment has been affected to some extent.
3. Ha Sanlian: annual mid-year net profit forecast 1892.11%, up 251.58% in the first half of 2021; Ha Sanlian affixed to the medical beauty of the reason is to participate in the Shierjia, most of the company's main products for the medical beauty supplies, including: medical hyaluronic acid Na repair stickers, medical hyaluronic acid Na repair liquid. The company holds 100% of the equity of North Star Pharmaceutical foreign investment, half-yearly report of the reason for the increase is mainly from the non-recurring gains and losses, the company recognized investment income on the company's 2021 consolidated statement of level of profit and loss impact amounted to about 56,600,000 yuan.
4. Huaxi biological annual mid-year report net profit forecast 35.00%, 102.23% increase in the first half of 2021; the company as the authentic leader of the medical beauty industry, currently belongs to the core high-tech enterprises, but also the world's leading hyaluronic acid microbial fermentation producers, but also the industrial scale also belongs to the forefront of the world, and is also one of the first to realize the microbial fermentation method of hyaluronic acid production enterprise It is also one of the first companies to realize the production of hyaluronic acid by microbial fermentation. In June last year, the company also acquired 100% of the equity of Foset, and opened the leading domestic hyaluronic acid series of products production equipment. The company's half-yearly report increased mainly because of the raw materials business as well as medical terminal business growth, its skin care business in the first half of the year is all the way to the momentum of the song, for the company to bring nearly 100% revenue growth. At the same time, in the revenue growth period the company also increased efforts to give strong support to the underlying scientific and technological research and development.
5. Lanzi shares: annual mid-year net profit forecast 3228.26%, up 105.52% in the first half of 2021; the three major domestic medical beauty brand "Milan", "crystal skin", "high", "life" are all by Lanzi. A lifetime" are held by Lancel, in the international market has also invested in South Korea's well-known medical beauty group DMG. This year, in addition to accelerating the pace in the women's fashion industry chain, it has also been advancing in medical beauty, realizing solid business development, which is important for the company's profit.
6. Haohai Shengke: annual mid-year net profit forecast 753.70%, up 192.55% in the first half of 2021; the company specializes in the field in the dermal filler hyaluronic acid, from the upstream raw materials to the terminal preparations of the whole industrial chain of research and development, production and sales capacity to two adapt to the current trend of the raw material production of the company. The company's performance changes mainly from the impact of the epidemic, the first half of this year, the epidemic has been effectively controlled, so as to carry out various marketing activities to expand the influence and increase product demand.
7. Specialty pharmaceuticals: annual mid-year net profit forecast 180.00%, 2021 first half rose 21.00%; the company intends to invest 100 million yuan to set up guangdong special beauty health science and technology industry limited company, the proposed establishment of the company for specialty pharmaceutical group of big health industry investment and operation platform, its development direction includes full layout of medical beauty services in the field of development and investment. The company's core product sales gradually incremental, the business also returned to normal levels, the company company constantly strengthen brand building, optimize product structure, increase internal management, adhere to the cost reduction and efficiency, has achieved better results.
8. Jinfa Rabi: annual mid-year net profit forecast 114.72%, up 139.51% in the first half of 2021; the company has an older seniority in the medical beauty industry, and invested in medical beauty enterprise Guangdong Hanfei Hospital, in the company's subsidiary is also holding five medical beauty institutions. The company's business plan in an orderly manner, the layout of online and offline channels, marketing strategy, management mode, product development mode adjustment, the company's income this year compared with the same period last year has a greater degree of recovery.
9. Chengzhi shares: annual mid-year net profit forecast 458.77%, up 24.54% in the first half of 2021; wholly owned subsidiary Chengzhi Life Science and Technology Co. official website shows that there is production of hyaluronic acid. Domestic supply and demand for medical beauty to last year after the epidemic has been significantly improved, clean energy business due to raw material price reversal, resulting in a substantial increase in sales of the company's related products, at the same time the company's company semiconductor liquid crystal display material market demand increased, production and sales volume increased significantly, also brought the company's profit increase.
10. Hui Long shares: annual mid-year net profit forecast 100.00%, up 35.71% in the first half of 2021; Haihua science and technology long-term attention to hyaluronic acid product production technology, and has been pilot production of related products. Shanghai Shaohua Biotechnology Development Co., Ltd, a subsidiary of Haihua Science and Technology, is mainly responsible for the company's future promotion of medical beauty products, sales, and technology research and development. The company's chemical trading business to adjust the business ideas, focusing on core suppliers, core customers, core products, strengthen control, operating results year-on-year growth.